Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective

BACKGROUND: Patients with β-thalassaemia major experience chronic iron overload due to regular blood transfusions. Chronic iron overload can be treated using iron-chelating therapies such as desferrioxamine (DFO), deferiprone (DFP) and deferasirox (DFX) monotherapy, or DFO–DFP combination therapy. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Bentley, Anthony, Gillard, Samantha, Spino, Michael, Connelly, John, Tricta, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757270/
https://www.ncbi.nlm.nih.gov/pubmed/23868464
http://dx.doi.org/10.1007/s40273-013-0076-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757270/
https://www.ncbi.nlm.nih.gov/pubmed/23868464
http://dx.doi.org/10.1007/s40273-013-0076-z

Ejemplares similares